Alnylam Announces FDA Approval of OXLUMO™ Injection for PH1
Alnylam (ALNY) announced that the US FDA has approved its subcutaneous OXLUMO™ (lumasiran) injection, the first-ever therapy available for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients.
Primary Hyperoxaluria Type 1
PH1 is an ultra-rare genetic disease. It is . . .
This content is for paid subscribers.
Today’s Highlights November 24, 2020